Michigan Medicine and the American Australian Asian Adrenal Alliance: International Collaboration to Study Adrenal Disorders
U-M is a leader in benign adrenal disorders which include primary aldosteronism (discovered by U-M endocrinologist Jerome Conn), hypercortisolism, and pheochromocytoma/paraganglioma (excess production of adrenaline). For many years, there has been a desire to bring together a large network of institutions to work collaboratively to study adrenal disorders in a manner unable to be accomplished by single institutions or by using existing large national databases.
Researchers have identified a gene that when inhibited or reduced, in turn, reduced or prevented human non-small cell lung cancer tumors from growing. When mice were injected with non-small cell lung cancer cells that contained the gene NOVA1, three of four mice formed tumors. When the mice were injected with cancer cells without NOVA1, three of four mice remained tumor-free.
The National Cancer Institute has awarded the University of Michigan Rogel Cancer Center a grant worth $33.4 million over five years. At the same time, the center’s designation as a “comprehensive cancer center” was renewed.
New research by Max Wicha, M.D., director of the Forbes Institute for Cancer Discovery, helps explain why stem cells become resistant to cancer treatment and opens a clever new way to go after them
A new study finds many breast cancer patients are concerned about the financial impact of their diagnosis and treatment, and that they feel their doctor’s offices are not helping with these concerns.
New research shows how to personalize the lung cancer screening decision for every patient. The results could help doctors fine-tune their advice to patients so that it’s based not only on a patient’s individual lung cancer risk and the potential benefits and harms of screening, but also the patient’s attitude about looking for problems and dealing with the consequences
A new Center of Excellence for Cancer Immunology and Immunotherapy (CECII) within the Rogel Cancer Center will widen U-M’s scope of cancer immunological clinical research, positioning the institution as a global leader in this hot area of cancer research.
An international consortium of labs tested nine different methods for RNA sequencing to understand and standardize the best methods for sequencing small RNAs. The goal was to create a process that could be reproduced from one lab to the next to the next.
Researchers led by the University of Michigan Rogel Cancer Center have identified a new subtype of prostate cancer that occurs in about 7 percent of patients with advanced disease.
The Association of American Cancer Institutes has established the Champion for Cures Award to recognize individuals who demonstrate significant leadership in supporting efforts to cure cancer and in inspiring others to do the same. The inaugural award will be presented to Richard and Susan Rogel, in recognition of their generous gift to the University of Michigan Rogel Cancer Center, which was renamed in their honor.